FLT PET/CT

OTHER6 trials

Sponsors

Masonic Cancer Center, University of Minnesota, The Catholic University of Korea, Rigshospitalet, Denmark, Shanghai Proton and Heavy Ion Center, Washington University School of Medicine

Conditions

Acute Myeloid LeukemiaCancerHematologic MalignancyMetastatic Prostate CarcinomaProstate CancerRecurrent Nasopharyngeal Carcinoma

Phase 1

Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer

RecruitingNCT04989946

University of Wisconsin, MadisonProstate Cancer

Start: 2021-12-16End: 2028-12-01Target: 60Updated: 2026-01-28

Phase 2

Immune Checkpoint Blockade Therapy Using 18F-FLT PET/CT

WithdrawnNCT04271436

Washington University School of MedicineCancer

Start: 2021-04-22End: 2025-01-31Updated: 2025-01-07

Unknown Phase

Pilot Study of Multi-Modality Imaging in Patients With Hematologic Malignancies

TerminatedNCT02042924

Masonic Cancer Center, University of MinnesotaHematologic Malignancy

Start: 2014-01-31End: 2015-11-30Updated: 2017-12-05

Early Response Assessment of Induction Chemotherapy in Acute Myeloid Leukemia Patients Using F-18 FLT PET/CT

CompletedNCT02103530

The Catholic University of KoreaAcute Myeloid Leukemia

Start: 2014-04-30End: 2015-12-31Updated: 2016-02-02

Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients

TerminatedNCT03011749

Rigshospitalet, DenmarkMetastatic Prostate Carcinoma

Start: 2017-01-31End: 2018-02-28Updated: 2019-09-12

Examine the Prognostic Role of FLT PET/CT for Patients With LR-NPC Treated by Carbon Ion Therapy

Shanghai Proton and Heavy Ion CenterRecurrent Nasopharyngeal Carcinoma

Start: 2020-07-31End: 2024-08-31Target: 40Updated: 2020-04-06

Related Papers

Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer.

2026-03-04